GlassScriptPhysician profile
Roopika Reddy
NPI 1760618516
$7,803.19
in general payments reported to CMS, 2019-2025
34 companies · $586 in 2025
The $586 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $600 · 2020: $108 · 2021: $222 · 2022: $4,616 · 2023: $1,112 · 2024: $561 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,146 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,145.52 |
| Education | $112.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,159.73 | 2022 | |
| Glaxosmithkline, LLC. | $554.31 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Jazz Pharmaceuticals INC. | $513.28 | 2019-2023 | Xywav |
| Harmony Biosciences LLC | $375.36 | 2021-2025 | Wakix |
| Astrazeneca Pharmaceuticals LP | $203.01 | 2019-2024 | Tezspire, Airsupra, Fasenra |
| Boston Scientific Corporation | $194.64 | 2021-2022 | |
| Grifols USA, LLC | $178.81 | 2019-2023 | Prolastin-C Liquid |
| Insmed, INC. | $168.71 | 2019-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $160.38 | 2023-2025 | Zerbaxa, Recarbrio, Winrevair |
| Actelion Pharmaceuticals US, INC. | $142.43 | 2019-2024 | Opsumit |
| Pulmonx Corporation | $130.05 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Bayer Healthcare Pharmaceuticals INC. | $124.00 | 2023 | |
| Sunovion Pharmaceuticals INC. | $121.52 | 2019-2020 | |
| United Therapeutics Corporation | $120.65 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.35 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $59.22 | 2025 | Ohtuvayre |
| Genzyme Corporation | $56.82 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $55.79 | 2022-2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $54.62 | 2024 | |
| Ambu INC. | $39.83 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.48 | 2023 | Glassia |
| Avadel Cns Pharmaceuticals, LLC | $33.18 | 2024-2025 | Lumryz |
| Mallinckrodt Enterprises LLC | $31.75 | 2019 | |
| Inspire Medical Systems, INC. | $31.62 | 2023 | Inspire |
| Vifor Pharma, INC. | $30.45 | 2024-2025 | Zemaira |
| Resmed Corp | $21.83 | 2019 | |
| Mallinckrodt Hospital Products INC. | $20.20 | 2025 | Acthar |
| Mylan Specialty L.P. | $20.14 | 2019 | |
| Ani Pharmaceuticals, INC. | $18.85 | 2022 | |
| Genentech USA, INC. | $16.92 | 2023 | Xolair |
| Viatris Specialty LLC | $15.70 | 2025 | Yupelri |
| Axsome Therapeutics, INC. | $14.39 | 2023 | Sunosi |
| Shire North American Group INC | $14.38 | 2019 | |
| Amgen INC. | $11.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roopika Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.